Epilepsy is a neurological disorder that affects millions of people worldwide. Over the years, significant advancements have been made in its management, providing new hope for patients and healthcare professionals alike.
Technological advancements have led to the development of more precise diagnostic tools. High-density EEGs and 3D-MRI imaging now allow for a more accurate localization of seizure foci. These tools have not only improved the diagnostic accuracy but also made it possible to identify surgical candidates earlier.
Newer antiepileptic drugs (AEDs) have been developed with better efficacy and fewer side effects. Drugs such as Brivaracetam and Perampanel have shown promising results in controlling seizures. Additionally, the use of CBD-based Epidiolex has been approved for certain types of epilepsy, expanding the therapeutic options.
Surgical management of epilepsy has also evolved, with minimally invasive techniques such as Laser Interstitial Thermal Therapy (LITT) and Responsive Neurostimulation (RNS) gaining popularity. These techniques have less postoperative morbidity and can be an option for patients who are not candidates for traditional resective surgery.
Neuromodulation therapies such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Transcranial Magnetic Stimulation (TMS) have emerged as effective adjunctive treatments. These therapies offer an alternative for patients who do not respond to pharmacological treatments or are not suitable for surgery.
The advancements in epilepsy management have significantly improved the quality of life for many patients. As healthcare professionals, it is imperative to stay updated with these advancements to provide the best care possible. These innovations, coupled with a personalized approach to treatment, will continue to improve the prognosis and quality of life for individuals living with epilepsy.
1.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
2.
Advances in "next generation" photoactive cancer therapy
3.
Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.
4.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
5.
FDA Approves New Bladder Cancer First-Line Standard of Care.
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
3.
The latest Hematocrit: An Overview of Red Blood Cell Health
4.
Contemporary Trends in Oncology and Patient Outcomes
5.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
3.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation